Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice

M. Gijs, G. Becker, A. Plenevaux, M. Bahri, A. Aerts, N. Impens, S. Baatout, A. Luxen
{"title":"Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice","authors":"M. Gijs, G. Becker, A. Plenevaux, M. Bahri, A. Aerts, N. Impens, S. Baatout, A. Luxen","doi":"10.4172/2155-9619.1000300","DOIUrl":null,"url":null,"abstract":"Background: Two novel HER2 aptamers were recently selected with great potential for the in vitro diagnosis of HER2-positive cancer. The goal of this study was to examine the in vivo diagnostic potential of these HER2 aptamers. Methods: Both HER2 aptamers were radiolabelled with 68Ga, injected in mice bearing a HER2-positive and HER2-negative tumour and evaluated by PET/MRI. Results: Ex vivo bio distribution analysis revealed high uptake in the blood, tissues and organs, except the brain. Interestingly, this high uptake was explained by the slow blood clearance due to non-specific aptamer binding to blood proteins. We observed accumulation of radioactivity in both tumours in time. Although higher uptake in the HER2-positive tumour compared to the HER2-negative tumour was observed, this was accompanied with more necrosis in the HER2-negative tumour, which was observed by 18FDG PET/CT. Conclusion: This work presents a first step towards the development of 68Ga-labelled aptamers for molecular cancer imaging.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"2013 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine and Radiation Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9619.1000300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: Two novel HER2 aptamers were recently selected with great potential for the in vitro diagnosis of HER2-positive cancer. The goal of this study was to examine the in vivo diagnostic potential of these HER2 aptamers. Methods: Both HER2 aptamers were radiolabelled with 68Ga, injected in mice bearing a HER2-positive and HER2-negative tumour and evaluated by PET/MRI. Results: Ex vivo bio distribution analysis revealed high uptake in the blood, tissues and organs, except the brain. Interestingly, this high uptake was explained by the slow blood clearance due to non-specific aptamer binding to blood proteins. We observed accumulation of radioactivity in both tumours in time. Although higher uptake in the HER2-positive tumour compared to the HER2-negative tumour was observed, this was accompanied with more necrosis in the HER2-negative tumour, which was observed by 18FDG PET/CT. Conclusion: This work presents a first step towards the development of 68Ga-labelled aptamers for molecular cancer imaging.
新型68ga放射性标记HER2适配体在小鼠体内的生物分布
背景:两种新的HER2适配体最近被选择出来,在体外诊断HER2阳性癌症方面具有很大的潜力。本研究的目的是检查这些HER2适体在体内的诊断潜力。方法:用68Ga对两种HER2适体进行放射性标记,注射到HER2阳性和HER2阴性肿瘤小鼠中,并通过PET/MRI进行评估。结果:体外生物分布分析显示,除脑外,血液、组织和器官均有高吸收量。有趣的是,这种高摄取可以解释为由于非特异性适配体与血液蛋白结合而导致的血液清除缓慢。我们及时观察到两个肿瘤中的放射性积累。尽管与her2阴性肿瘤相比,her2阳性肿瘤的摄取更高,但18FDG PET/CT观察到,her2阴性肿瘤伴有更多的坏死。结论:本研究为开发用于肿瘤分子成像的68ga标记适配体迈出了第一步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信